One of integrative medicine’s greatest foes got re-elected. But it’s not all bad. Here’s an overview of what we can expect in the months ahead. State-based Action Alert! The 114th Congress was sworn in on January 3. Republicans now control both chambers, but lack the supermajority needed in the Senate to pass legislation—and of course President […]
We couldn’t have done it without you, and the help of other health advocacy organizations. Much more remains to be accomplished in 2015. Nutrition Facts Panel FDA proposed a new 109-page set of rules for revising nutrition and supplement labels. It included a provision that would have banned the word “folate” from supplement labels, even though […]
Three innovative products, but only one has the official go-ahead. Why can’t the government get out of the way and let women protect themselves?
Natural health foes may once again try this deceptive trick to enact legislation to benefit Big Pharma or Big Farma. Negotiations between the House and the Senate are currently underway to pass a $1.1 trillion appropriations bill. It or something else must be passed by Thursday night if a government shutdown in January is to […]
Natural health foes may once again try this deceptive trick to enact legislation to benefit Big Pharma or Big Farma.
Companies claim that the blanket denial of coverage of compounding ingredients is against federal law. It could also affect access to critical natural health products. Action Alert! In August we told you about pharmacy benefit managers (PBMs)—companies that process prescriptions for insurance companies and corporations, and use their size to negotiate low prices with drug makers and pharmacies. They […]
Researchers may now have to make clinical study results public— even if the results run counter to the interests of Big Pharma. Action Alert! In response to mounting concerns that important health data has been kept hidden from physicians and their patients, the National Institutes of Health (NIH) and the Department of Health and Human Services […]
If you thought the FDA was hostile only to supplements, think again. The agency is also unfriendly to drugs no longer under patent. Aspirin is a very old drug. It is no longer under patent protection, which means there is no longer any financial windfall to be made from it. We have reservations about taking […]
—and why their decision will have far-reaching ramifications for state licensing boards. Last year we told you about the Federal Trade Commission’s investigation of the North Carolina dental board. The FTC decided the board had attempted to monopolize the teeth whitening business, and found it had illegally thwarted competition through cease-and-desist letters. The board—composed mainly of private dentists—had […]
Recent regulations released by the FDA contain several provisions that are harmful to doctors, patients, and compounding pharmacists. Office Use: This is an area of the rulemaking that has garnered the biggest reaction from the compounding community. Congress and the FDA have required a patient-specific prescription for all drugs compounded, with a narrow exception if […]